While shares of Verastem (NASDAQ:VSTM) have tripled over the past year, looking at the three-year period, they are still in the red by around 40%.
On September 6th, the company announced positive top-line results from its pivotal DUO trial (n=319) examining in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The study evaluated its drug candidate duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated attorneys Stephanie M. Chesney
Burns & Levinson announced today that well-known plaintiff employment litigator Beth R. Myers has joined the firm
BayCoast Bank is delighted to announce Nicole Almeida as Senior Vice President, Chief Diversity Officer (CDO)
BayCoast Bank is pleased to announce Robert Bergdoll of Attleboro, Massachusetts, as First Vice President Marketing Director
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
